Current therapeutic strategies for these conditionssuch as oral small-molecule drugs, systemic chemotherapy, or surgical intervention are often constrained by limitations, including poor targeting efficiency, rapid drug degradation, significant off-target side effects, and difficulty in penetrating diseased tissues (e.g., tumor stroma or inflamed mucosa) [7, 8]
However, these studies cannot definitely establish the absence of any risk because of methodological limitations including small sample size and some lacking comparator groups
Clinical trial data shows patients typically lose 5-10 pounds total by week eight, with momentum accelerating if dose escalation occurs
High re-infection rates cause persistence of human liver fluke infections
Some are deciding whether to